As of 2024-12-15, the EV/EBITDA ratio of HLS Therapeutics Inc (HLS.TO) is 11.35. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. HLS.TO's latest enterprise value is 188.43 mil CAD. HLS.TO's TTM EBITDA according to its financial statements is 16.60 mil CAD. Dividing these 2 quantities gives us the above HLS.TO EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 9.8x - 10.9x | 10.4x |
| Forward P/E multiples | 10.0x - 13.0x | 12.0x |
| Fair Price | 5.03 - 7.39 | 6.07 |
| Upside | 38.1% - 103.0% | 66.8% |
| Date | EV/EBITDA |
| 2024-12-13 | 7.98 |
| 2024-12-12 | 7.99 |
| 2024-12-11 | 7.79 |
| 2024-12-10 | 7.67 |
| 2024-12-09 | 7.72 |
| 2024-12-06 | 7.65 |
| 2024-12-05 | 7.67 |
| 2024-12-04 | 7.80 |
| 2024-12-03 | 7.81 |
| 2024-12-02 | 7.87 |
| 2024-11-29 | 7.94 |
| 2024-11-28 | 7.85 |
| 2024-11-27 | 7.80 |
| 2024-11-26 | 7.85 |
| 2024-11-25 | 7.79 |
| 2024-11-22 | 7.68 |
| 2024-11-21 | 7.53 |
| 2024-11-20 | 7.29 |
| 2024-11-19 | 7.40 |
| 2024-11-18 | 7.33 |
| 2024-11-15 | 7.36 |
| 2024-11-14 | 7.45 |
| 2024-11-13 | 7.61 |
| 2024-11-12 | 7.73 |
| 2024-11-11 | 7.99 |
| 2024-11-08 | 7.99 |
| 2024-11-07 | 8.06 |
| 2024-11-06 | 7.65 |
| 2024-11-05 | 7.56 |
| 2024-11-04 | 7.52 |
| 2024-11-01 | 7.45 |
| 2024-10-31 | 7.57 |
| 2024-10-30 | 7.65 |
| 2024-10-29 | 7.75 |
| 2024-10-28 | 7.79 |
| 2024-10-25 | 7.80 |
| 2024-10-24 | 8.25 |
| 2024-10-23 | 8.29 |
| 2024-10-22 | 8.26 |
| 2024-10-21 | 8.27 |
| 2024-10-18 | 8.33 |
| 2024-10-17 | 8.39 |
| 2024-10-16 | 8.34 |
| 2024-10-15 | 8.45 |
| 2024-10-11 | 8.14 |
| 2024-10-10 | 8.06 |
| 2024-10-09 | 8.15 |
| 2024-10-08 | 8.38 |
| 2024-10-07 | 7.92 |
| 2024-10-04 | 7.99 |